The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지

New Drug Development using Korean Herbal Formulae: A model role study

  • Cho, Jung-Hyo (Liver-Immune Department of Oriental Medicine College, Daejeon University) ;
  • Wang, Jing-Hua (Liver-Immune Department of Oriental Medicine College, Daejeon University) ;
  • Son, Chang-Gue (Liver-Immune Department of Oriental Medicine College, Daejeon University)
  • Published : 2009.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Traditional Korean herbal formulae are composed of multiple medicinal plants. This situation of multiple-ingredient mixtures has been considered as a major obstacle to new drug development using herbal formulae in the world market, despite the effectiveness of such mixtures. This study reviewed Liv-52 as a representative model of successful drug development using a multiple-herb mixture. Methods: All articles for Liv-52 were collected from the PubMed database. The history, composition of Liv-52, its pharmaceutical efficacy and mechanisms, and data from clinical studies including its market size were analyzed. Results: Liv-52 is composed of seven herbal plants and it is the best known in Ayurvedic medicine for treating liver disorders. Since its 1955 introduction, forty four international papers have been published based on pre-clinical and clinical trials. The efficacy and mechanisms of Liv-52 were intensively studied. Currently, Liv-52 is one of the top-selling products, with over 10 million dollars sales annually, in the world market. Conclusions: These results indicate that Korean herbal formulae could be new global drugs if scientific evidence for efficacy and standardization are produced via literature researches.

Keywords

References

  1. Korea Health Industry Development Institute. Market Trend of Korean traditional medicine industry. Health Industry White Paper. 2006:4-6, Korean.
  2. De Smet PA. Herbal remedies. N Engl J Med. 2002; 347:2046-56. https://doi.org/10.1056/NEJMra020398
  3. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL International Consensus Conference on Hepatitis B. J Hepatol. 2003; 39(1):S3-S25. https://doi.org/10.1016/S0168-8278(03)00213-7
  4. Graf TN, Wani MC, Agarwal R, Kroll DJ, Oberlies NH. Gram-Scale Purification of Flavonolignan Diastereoisomers from Silybum marianum (Milk Thistle) Extract in Support of Preclinical in vivo Studies for Prostate Cancer Chemoprevention. Planta Med. 2007; 73(14):1495-501. https://doi.org/10.1055/s-2007-990239
  5. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine: Indian J Med Res. 20061; 24(5):491-504.
  6. Levy C, Seeff LD, Lindor KD. Use of herbal supplements for chronic liver disease. Clin Gastroenterol Hepatol. 2004; 2(11):947-56. https://doi.org/10.1016/S1542-3565(04)00455-0
  7. Available from URL: http://liv52.com
  8. Fleig WW, Morgan MY, Holwer MA. European multicenter study group. The Ayurvedic drug Liv-52 in patients with alcoholic cirrhosis. Results of a prospective, randomized, double-blind, placebo-controlled clinical trial. J Hepatol. 1997; 26(supple):127.
  9. Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Digestive and Liver Disease. 2007; 39:293-304. https://doi.org/10.1016/j.dld.2006.11.004
  10. Huseini HF, Alavian SM, Heshmat R, Heydari MR, Abolmaali K. The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach. Phytomedicine. 2005; 12(9):619-24. https://doi.org/10.1016/j.phymed.2004.10.003
  11. Available from URL: http://www.favorfinesse.com/liv-52.shtml
  12. Germano MP, De Pasquale R, D'Angelo V, Catania S, Silvari V, Costa, C. Evaluation of extracts and isolated fraction from Capparis spinosa L. buds as an antioxidant source. J. Agric. Food Chem. 2002; 50(5):1168-71. https://doi.org/10.1021/jf010678d
  13. Gilani AH, Janbaz KH, Shah BH. Esculetin prevents liver damage induced by paracetamol and CCL4. Pharmacol. Res. 1998; 37:31-5. https://doi.org/10.1006/phrs.1997.0262
  14. Gilani AH, Janbaz KH, Shah BH, Martin-Aragon S, Benedi JM, Villar AM. Effects of the antioxidant (6,7-dihydroxycoumarin) esculetin on the glutathione system and lipid peroxidation in mice. Gerontology. 1998; 44:21-5. https://doi.org/10.1159/000021978
  15. Sumitra M, Manikandan P, Kumar DA, Arutselvan N, Balakrishna K, Manohar BM, et al. Experimental myocardial necrosis in rats: role of arjunolic acid on platelet aggregation, coagulation and antioxidant status. Mol. Cell. Biochem. 2001; 224(1-2):135-42. https://doi.org/10.1023/A:1011927812753
  16. Sultana S, Perwaiz S, Iqbal M, Athar M. Crude extracts of hepatoprotective plants, Solanum nigrum and Cichorium intybus inhibit free radical-mediated DNA damage. J. Ethnopharmacol. 1995; 45:189-92. https://doi.org/10.1016/0378-8741(94)01214-K
  17. Jafri MA, Jalis Subhani M, Javed K, Singh S. Hepatoprotective activity of leaves of Cassia occidentalis against paracetamol and ethyl alcohol intoxication in rats. J. Ethnopharmacol. 1999; 66(3):355-61. https://doi.org/10.1016/S0378-8741(99)00037-9
  18. Candan F, Unlu M, Tepe B, Daferera D, Polissiou M, Sokmen A, Akpulat HA. Antioxidant and antimicrobial activity of the essential oil and methanol extracts of Achillea millefolium subsp. millefolium Afan. (Asteraceae). J. Ethnopharmacol. 2003; 87(2-3):215-20. https://doi.org/10.1016/S0378-8741(03)00149-1
  19. de Silva HA, Saparamadu PA, Thabrew MI, Pathmeswaran A, Fonseka MM, de Silva HJ. Liv.52 in alcoholic liver disease: a prospective, controlled trial. J Ethnopharmacol. 2003; 84(1):47-50. https://doi.org/10.1016/S0378-8741(02)00263-5
  20. Kalab M, Krechler T. The effect of the hepatoprotective agent LIV 52 on liver damage. Cas Lek Cesk. 1997; 136(24):758-60.
  21. Hauhan BL, Kulkarni RD. Effect of Liiv 52, a herbal preparation, on absorption and metabolism of ethanol in humans. Eur J Clin Pharmacol. 1991; 40(2):189-91.
  22. Chauhan BL, Kulkarni RD. Alcohol hangover and Liv 52. Eur J Clin Pharmacol. 1991; 40(2):187-8.
  23. Desai IV, Dudhia MV, Gandhi VK. A clinical study of infective hepatitis treated with Liv 52. Indian Pediatr. 1977; 14(3):197-202.
  24. Sama SK, Krishnamurthy L, Ramachandran K, Lal K. Efficacy of an indigenous compound preparation (Liv-52) in acute viral hepatitis-a double blind study. Indian J Med Res. 1976; 64(5):738-42.
  25. Ramalingam V, Sundaravalli N, Raju VB. Liv. 52 studies in acute hepatitis. Indian Pediatr. 1971; 8(12):839-42.
  26. Nigam P, Dayal SG, Mukhija RD, Goyal BM, Joshi LD. Hepato-protective role of indigenous drug Liv-52 in lepromatous leprosy. Hansenol Int. 1982; 7(1):36-44.
  27. Rao PT, Khan AM, Anjaiah K. Comparative trial of Liv 52. and Orabolin in marasmus. Indian J Pediatr. 1972; 39(294):227-30. https://doi.org/10.1007/BF02752466
  28. McPhail DB, Hartley RC, Gardner PT, Duthie GG. Kinetic and stoichiometric assessment of the anti-oxidant activity of flavonoids by electron spin resonance spectroscopy. J. Agric. Food Chem. 2003; 51(6): 1684-1690. https://doi.org/10.1021/jf025922v
  29. Saxena A, Garg NK. Effect of Liv-52 on hepatic enzymes. Indian J Exp Biol. 1979; 17(7):662-4.
  30. Saxena A, Garg NK. Effect of Liv-52 on membrane lipids in carbon tetrachloride-induced hepatotoxicity in rats. Indian J Exp Biol. 1981; 19(9):859-62.
  31. Gopumadhavan S, Jagadeesh S, Chauhan BL, Kulkarni RD. Protective effect of Liv-52 on alcohol-induced fetotoxicity. Alcohol Clin Exp Res. 1993; 17(5):1089-92. https://doi.org/10.1111/j.1530-0277.1993.tb05669.x
  32. Roy A, Soni GR, Kolhapure RM, Karnik UR, Patki PS. Down regulation of tumour necrosis factor activity in experimental hepatitis by a herbal formulation, Liv-52. Indian J Exp Biol. 1994; 32(10):694-7.
  33. Suja V, Sharmila SL, Shyamala Devi C. Protective effect of Liv.52 and Liv.100, Ayurvedic formulations on lipid peroxidation in rat liver homogenate--an in vitro study. Indian J Exp Biol. 1997 Jan; 35(1):50-2.
  34. Available from http://www.himalayahealthcare.com/pressroom/news182.htm
  35. Firenzuoli F, Gori L. Herbal medicine today: clinical and research issues. Evid Based Complement Alternat Med 2007; 4:37-40. https://doi.org/10.1093/ecam/nem096
  36. Ghosh AK. Clinical applications and update on evidence-based medicine. J Assoc Physicians India 2007; 55:787-94.
  37. Jadad AR, Moore RA, Carrol D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 199617:112. https://doi.org/10.1016/0197-2456(96)84655-1